Ahold Delhaize USA Inc. has agreed to pay $40 million to resolve allegations under the False Claims Act that pharmacies operating within its Giant, Hannaford, Stop & Shop, and Food Lion stores reported inflated 'usual and customary' drug prices to Medicare, Medicaid, and TRICARE. Approximately $32.9 million of the settlement will go to the federal government, with the remainder allocated to participating states. The matter underscores the Department of Justice's sustained focus on pharmacy pricing practices and the financial exposure that can result when discount program prices are excluded from price reporting to federal healthcare programs.
At the core of the government's allegations was the contention that the relevant pharmacies failed to disclose lower prices available through customer savings or membership programs when reporting their 'usual and customary' prices. Under longstanding DOJ enforcement positions, prices that are routinely offered to a meaningful segment of cash-paying customers ΓÇö including through discount or membership programs ΓÇö should be reflected in the 'usual and customary' price reported to federal payors. Reporting a higher price while concurrently offering lower prices to a substantial customer base can expose pharmacies to significant FCA liability, including treble damages and per-claim penalties.
The case carries particular significance for retail and chain pharmacies that maintain multi-tier pricing structures. Compliance frameworks should account for the interplay between promotional pricing, loyalty programs, and federal price reporting obligations. Pharmacies should evaluate whether their methodologies for determining 'usual and customary' prices appropriately capture discounted rates routinely offered to the public, and whether internal audit procedures are calibrated to detect deviations across store locations and pricing platforms.
The settlement also reinforces the central role of whistleblowers in pharmacy enforcement. The matter originated from a qui tam action filed by a former pharmacist, illustrating how employees with direct visibility into pricing operations continue to drive FCA investigations. Companies operating in the pharmacy sector should reassess internal reporting channels, ensure employees can raise concerns without fear of retaliation, and respond promptly to internal complaints regarding pricing methodologies.
This alert is provided for general informational purposes only and does not constitute legal advice. Clients facing FCA exposure or pharmacy pricing compliance questions should consult counsel for guidance tailored to their specific circumstances.